These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 19240944)

  • 1. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
    Cuevas C; Francesch A
    Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
    Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
    Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
    Wright BJ; Chan C; Danishefsky SJ
    J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
    Le VH; Inai M; Williams RM; Kan T
    Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and clinical results with the natural marine product ET-743.
    D'Incalci M; Jimeno J
    Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
    Jin W; Metobo S; Williams RM
    Org Lett; 2003 Jun; 5(12):2095-8. PubMed ID: 12790537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique features of trabectedin mechanism of action.
    Larsen AK; Galmarini CM; D'Incalci M
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs from the sea.
    D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
    J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.
    Allavena P; Signorelli M; Chieppa M; Erba E; Bianchi G; Marchesi F; Olimpio CO; Bonardi C; Garbi A; Lissoni A; de Braud F; Jimeno J; D'Incalci M
    Cancer Res; 2005 Apr; 65(7):2964-71. PubMed ID: 15805300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereospecific formal total synthesis of ecteinascidin 743.
    Zheng S; Chan C; Furuuchi T; Wright BJ; Zhou B; Guo J; Danishefsky SJ
    Angew Chem Int Ed Engl; 2006 Mar; 45(11):1754-9. PubMed ID: 16496274
    [No Abstract]   [Full Text] [Related]  

  • 17. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
    Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
    Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells.
    Acikgoz E; Guven U; Duzagac F; Uslu R; Kara M; Soner BC; Oktem G
    PLoS One; 2015; 10(10):e0141090. PubMed ID: 26485709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
    Atmaca H; Uzunoglu S
    Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.